{
    "data": [
        {
            "id": "1822752",
            "type": "article",
            "attributes": {
                "publishOn": "2013-11-08T11:53:57-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Geron's Promising News Poses No Threat To Incyte",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "124460",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1822752-gerons-promising-news-poses-no-threat-to-incyte"
            }
        },
        {
            "id": "1555822",
            "type": "article",
            "attributes": {
                "publishOn": "2013-07-18T13:28:18-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte Is Positioning For A Strong 2nd Half",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "35761",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "118932",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1555822-incyte-is-positioning-for-a-strong-2nd-half"
            }
        },
        {
            "id": "1531192",
            "type": "article",
            "attributes": {
                "publishOn": "2013-07-02T09:17:44-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte: Financial Projection And Stock Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32731",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "118230",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1531192-incyte-financial-projection-and-stock-valuation"
            }
        },
        {
            "id": "1522442",
            "type": "article",
            "attributes": {
                "publishOn": "2013-06-26T11:58:40-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Sources Of Revenue For Incyte",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32731",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "117966",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1522442-3-sources-of-revenue-for-incyte"
            }
        },
        {
            "id": "1520232",
            "type": "article",
            "attributes": {
                "publishOn": "2013-06-25T12:08:18-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Much Should You Pay For Incyte?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32731",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "117908",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1520232-how-much-should-you-pay-for-incyte"
            }
        },
        {
            "id": "1230661",
            "type": "article",
            "attributes": {
                "publishOn": "2013-02-27T15:36:23-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte's Jakafi Is Likely A $1 Billion Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20772",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "112399",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1230661-incytes-jakafi-is-likely-a-1-billion-drug"
            }
        },
        {
            "id": "1156061",
            "type": "article",
            "attributes": {
                "publishOn": "2013-02-05T03:13:39-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte Pharmaceuticals Is Primed For A Run",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "111348",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/1156061-incyte-pharmaceuticals-is-primed-for-a-run"
            }
        }
    ]
}